去年，Twist Bioscience Corp表现最佳的业务板块NGS tools实现营收208.10M美元。Americas的营收贡献最高，去年达到225.58M美元。最近一个季度，截至2026-06-30，Twist Bioscience Corp表现最佳的业务板块NGS applications实现营收61.80M美元。Americas的营收贡献最高，达到77.26M美元。

业务

营业收入

占比

年报

年报

单季报

NGS tools

Synthetic genes

Antibody discovery

Oligo pools

DNA libraries

DNA and Biopharma libraries

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

NGS tools

208.10M(55.26%)

169.13M(51.74%)

123.71M(48.45%)

99.31M(48.79%)

72.67M(54.91%)

44.02M(48.85%)

21.04M(38.69%)

2.67M(10.49%)

72.00K(0.67%)

--(--)

Synthetic genes

113.60M(30.17%)

92.68M(28.35%)

73.54M(28.80%)

61.51M(30.22%)

38.96M(29.44%)

35.19M(39.06%)

26.71M(49.12%)

17.99M(70.74%)

8.12M(75.43%)

1.09M(47.91%)

Antibody discovery

23.45M(6.23%)

20.33M(6.22%)

23.17M(9.08%)

24.17M(11.87%)

--(--)

Oligo pools

20.23M(5.37%)

16.91M(5.17%)

14.49M(5.68%)

12.42M(6.10%)

8.04M(6.07%)

4.54M(5.04%)

4.59M(8.45%)

3.00M(11.81%)

2.06M(19.10%)

862.00K(37.99%)

DNA libraries

11.18M(2.97%)

13.93M(4.26%)

10.20M(4.00%)

6.15M(3.02%)

--(--)

DNA and Biopharma libraries

--(--)

13.93M(4.26%)

10.20M(4.00%)

--(--)

12.66M(9.57%)

6.35M(7.05%)

2.04M(3.74%)

1.77M(6.97%)

517.00K(4.80%)

320.00K(14.10%)

地区

营业收入

占比

年报

年报

单季报

Americas

EMEA

APAC

United States

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

Americas

225.58M(59.90%)

193.88M(61.95%)

151.26M(61.71%)

122.47M(60.16%)

77.91M(58.87%)

1.08M(1.20%)

996.00K(1.83%)

207.00K(0.81%)

227.00K(2.11%)

--(--)

EMEA

124.24M(32.99%)

92.57M(29.58%)

71.39M(29.13%)

62.08M(30.50%)

44.12M(33.34%)

25.82M(28.66%)

14.69M(27.01%)

6.56M(25.79%)

2.02M(18.79%)

459.00K(20.23%)

APAC

26.75M(7.10%)

26.52M(8.47%)

22.46M(9.16%)

19.01M(9.34%)

10.30M(7.78%)

5.12M(5.68%)

2.76M(5.08%)

1.00M(3.94%)

274.00K(2.54%)

41.00K(1.81%)

United States

--(--)

58.08M(64.46%)

35.94M(66.08%)

17.66M(69.46%)

8.24M(76.56%)

1.77M(77.96%)